Literature DB >> 8957733

Symptom-specific use of upper gastrointestinal endoscopy in human immunodeficiency virus-infected patients yields high dividends.

R M Bashir1, C M Wilcox.   

Abstract

The yield of upper gastrointestinal endoscopy (esophago-gastroduodenoscopy; EGD) in human immunodeficiency virus (HIV)-infected patients based on presenting symptoms has not been well studied. We studied consecutive patients with documented HIV infection undergoing EGD at a large innercity hospital between August 1, 1990 and December 31, 1993; all had presenting symptoms and indications for EGD prospectively recorded at the time of EGD. All endoscopic abnormalities were routinely subjected to biopsy, and extensive histopathological evaluation was performed. EGD was considered helpful when the findings stimulated specific therapeutic intervention other than antifungal or antacid medications. The specific indications for EGD in 156 patients were as follows: esophageal symptoms, 102 patients (65%); abdominal pain, 18 (12%); upper gastrointestinal bleeding, 25 (16%); refractory nausea and vomiting, 11 (7%). Overall, pathologic findings were identified in 116 patients (74%): in refractory esophageal symptoms, 82%; upper gastrointestinal bleeding, 92%; abdominal pain, 39%; nausea and vomiting, 27%. EGD with biopsy identified a specifically treatable opportunistic disorder other than Candida in 80 patients (51%), including idiopathic esophageal ulcer (22%) or viral esophagitis and/or duodenitis (29%). EGD was not helpful in 22.3% of cases, those involving Candida (12.3%) and peptic ulcer disease (PUD)-related causes (10%). The mean CD4 count of patients with opportunistic pathologic findings (24/mm3, n = 79) was significantly lower than that of patients with PUD/gastroesophageal reflux disease (GERD) (167/mm3, n = 9) or negative EGDs (165/mm3, n = 35). Overall, the results of EGD influenced patient management in 78% of cases. We conclude that selective symptom-specific use of EGD, particularly in patients with esophageal symptoms refractory to antifungal therapy or gastrointestinal bleeding, usually identifies specifically treatable abnormalities, whereas EGD is less useful for the evaluation of abdominal pain or nausea and vomiting.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957733     DOI: 10.1097/00004836-199612000-00011

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  5 in total

1.  Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

Authors:  Parya Saberi; Dilrini K Ranatunga; Charles P Quesenberry; Michael J Silverberg
Journal:  Pharmacotherapy       Date:  2011-03       Impact factor: 4.705

Review 2.  Impact of changing epidemiology of gastroesophageal reflux disease on its diagnosis and treatment.

Authors:  Hugo Bonatti; Sami R Achem; Ronald A Hinder
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

3.  Outcome of index upper gastrointestinal endoscopy in patients presenting with dysphagia in a tertiary care hospital-A 10 years review.

Authors:  Nafees A Qureshi; Michael T Hallissey; John W Fielding
Journal:  BMC Gastroenterol       Date:  2007-11-22       Impact factor: 3.067

4.  Prevalence of and risk for gastrointestinal bleeding and peptic ulcerative disorders in a cohort of HIV patients from a U.S. healthcare claims database.

Authors:  Emily Bratton; Vani Vannappagari; Monica G Kobayashi
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 5.  Small intestine pathogens in AIDS: conventional and opportunistic.

Authors:  J Koch; R L Owen
Journal:  Gastrointest Endosc Clin N Am       Date:  1998-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.